DUBAI (March 12, 2026) – Prof. Mirza R. Baig, Professor of Pharmacy Practice at Dubai Medical University, recently delivered a talk on “Embedding Pharmacovigilance Activities in Clinical Trials” at the 5th Edition Drug Safety Symposium 2026 – Middle East Chapter.

Prof. Baig emphasized the critical importance of integrating pharmacovigilance early in clinical trial design to enable early signal detection, proactive risk management, and enhanced patient safety, ensuring that safety systems are built in, not added later. His insights strongly reinforced the role of academic leadership in shaping safer, more ethically grounded clinical research.

Acknowledged as a leading pharmacovigilance (PV) event in the region, the symposium persists in its objective to enhance patient safety and regulatory standards throughout the Middle East. The 2026 edition, titled “Pharmacovigilance 360°: Building Patient Safety from Clinical Trials to Post-Market,” provided an in-depth examination of drug safety throughout the complete product lifecycle, spanning from clinical research to real-world implementation.